Please login to the form below

Not currently logged in
Email:
Password:

Mochida and Wyeth in novel vanilloid pain tie-up

Mochida licenses a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals

Mochida Pharmaceutical has licensed a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists for use as a potential novel treatment for pain to Wyeth Pharmaceuticals.

Per the Agreement, Wyeth wins an exclusive worldwide license to develop, manufacture, use and sell pharmaceutical products containing Mochida's TRPV1 antagonists. Mochida will receive an upfront payment and potential development milestone payments, as well as royalties on sales by Wyeth.

Mochida retains an option to co-develop and co-market in Japan with Wyeth.

TRPV1 is a receptor and ion channel, which is stimulated by various stimuli including capsaicin, an ingredient derived from chilli peppers.

A number of other large pharmaceutical companies are also researching TRPV1 receptors for use in reducing nociception from inflammatory and neuropathic pain models in rats. In humans, drugs acting at TRPV1 receptors could potentially be used to treat neuropathic pain associated with multiple sclerosis, chemotherapy, or amputation, as well as pain associated with the inflammatory response of damaged tissue, such as in osteoarthritis. Existing painkillers sometimes cause gastrointestinal disorders or renal disorders, which limits their use.

14th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics